Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype

被引:46
作者
Lipworth, BJ [1 ]
Dempsey, OJ [1 ]
Aziz, I [1 ]
Wilson, AM [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland
关键词
D O I
10.1016/S0002-9343(00)00454-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor. We assessed the effects of adding treatment with either a long-acting beta(2)-agonist (inhaled formoterol, 12 mu g twice daily) or a leukotriene receptor antagonist (oral zafirlukast, 20 mg twice daily) to inhaled corticosteroid therapy in patients with this genotype. SUBJECTS AND METHODS: We enrolled 24 patients with mild to moderate asthma who were being treated with inhaled corticosteroids. Patients were randomly assigned to receive one of three treatments (placebo, zafirlukast, or formoterol in addition to inhaled corticosteroids) for 1 week each in a crossover fashion, separated by a 1-week placebo run-in and washout period. Measurements of bronchoprotection (measured as the provocative dose of methacholine that produced a 20% decline in forced expiratory volume in 1 second [FEV1]), exhaled nitric oxide (a surrogate marker of airway inflammation), and symptoms were made before each treatment and 12 hours after the last dose of each treatment. RESULTS: Both formoterol and zafirlukast were equally effective in maintaining asthma control compared with placebo: the geometric mean-fold difference in the methacholine provocative dose was 1.5-fold (95% confidence interval [CI]: 1.1- to 2.2-fold) for zafirlukast and 1.9-fold (95% CI: 1.2- to 2.9-fold) for formoterol. As compared with placebo, zafirlukast caused a significant suppression in exhaled nitric oxide (1.7-fold difference in geometric mean values, 95% CT: 1.1- to 2.6-fold) but formoterol did not (1.2-fold difference, 95% Cl: 0.8- to 1.9-fold). Diary cards showed significant (P < 0.05) improvements in the peak flow with formoterol (morning and evening) and zafirlukast (evening) as compared with placebo. CONCLUSIONS: Formoterol and zafirlukast maintained asthma control in patients who might he genetically predisposed to fare worse with long-acting beta(2)-agonists. The reduction in exhaled nitric oxide with zafirlukast suggests that it may have anti-inflammatory effects in addition to those seen with inhaled corticosteroids. Am J Med. 2000;109:114-121. (C) 2000 by Excerpta Medica, Inc.
引用
收藏
页码:114 / 121
页数:8
相关论文
共 38 条
  • [31] Rosenthal R, 1996, J ALLERGY CLIN IMMUN, V97, P270
  • [32] Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment
    Sont, JK
    Willems, LNA
    Bel, EH
    van Krieken, JHJM
    Vandenbroucke, JP
    Sterk, PJ
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) : 1043 - 1051
  • [33] Association between beta(2)-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
    Tan, S
    Hall, IP
    Dewar, J
    Dow, E
    Lipworth, B
    [J]. LANCET, 1997, 350 (9083) : 995 - 999
  • [34] Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma
    van Noord, JA
    Schreurs, AJM
    Mol, SJM
    Mulder, PGH
    [J]. THORAX, 1999, 54 (03) : 207 - 212
  • [35] The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma
    Wallin, A
    Sandström, T
    Söderberg, M
    Howarth, P
    Lundbäck, B
    Della-Cioppa, G
    Wilson, S
    Judd, M
    Djukanovic, R
    Holgate, S
    Lindberg, A
    Larssen, L
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (01) : 79 - 86
  • [36] WESTBROEK J, 1997, EUR RESP J S25, V19, pS248
  • [37] Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma
    Wilson, AM
    Lipworth, BJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 2000, 108 (04) : 269 - 275
  • [38] Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
    Woolcock, A
    Lundback, B
    Ringdal, N
    Jacques, LA
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (05) : 1481 - 1488